Please login to the form below

Glybera

This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut

Latest news

UniQure’s starts pivotal haemophilia B gene therapy trial

UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
NICE backs GSK’s €594k gene therapy for rare disease

Strimvelis was approved by the EMA in 2016 - the second gene therapy to get a green light anywhere in the world after UniQure’s $1m Glybera (alipogene tiparvovec) product for lipoprotein
Spark’s Luxturna becomes US’s first approved gene therapy

UniQure charged $1m for its Glybera (alipogene tiparvovec) product for lipoprotein lipase deficiency (LPLD) - the first gene therapy approved in Europe - but that product was withdrawn from the market this year
Spark closes on first US gene therapy approval

The first (and so far only) gene therapy to reach the market in the EU - UniQure/Chiesi's 1m-per-treatment Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency (LPLD) - was withdrawn

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Bluebird Bio: on the cusp of a gene therapy revolution

success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
Health on instalment

Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
Rare diseases: meeting the challenge

Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
Pharma deals in April 2015

Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per
Anticipating the future in healthcare

As a gene therapy, Glybera is injected through a one-time course of up to 60 consecutive intramuscular injections. ... The introduction of therapies such as Glybera and Holostem will have significant implications on the healthcare ecosystem.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Basilea's Hans Christian Rohde takes up commercial role at uniQure

In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

The gene therapy revolution

There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Director Healthcare PR Communications: Salary TBC

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Senior Account Executive – Medical Communications: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, Healthcare Advertising: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior Systematic Review Analyst - Oxford: Negotiable

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Project / Account Manager (Medical Education): Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

Editorial Director – Medical Education: Neg

Director – Head of Public Affairs: Neg

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director – Global Healthcare PR: Salary TBC

Associate Medical Director: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Account Director: Negotiable

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Senior Medical Writer (Remote Working): Competitive Salary Offered

Scientific Team Lead: Competitive Salary

Associate Medical Director: Highly Competitive

Subscribe to our email news alerts

PMHub

Add my company

Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...